tiprankstipranks
HLS Therapeutics Inc (DE:74D)
FRANKFURT:74D

HLS Therapeutics Inc (74D) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

74D Analyst Ratings

Hold
1Ratings
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
HLS
Therapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

74D Stock 12 Months Forecast

Average Price Target

€2.95
▲(6.95% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for HLS Therapeutics Inc in the last 3 months. The average price target is €2.95 with a high forecast of €2.95 and a low forecast of €2.95. The average price target represents a 6.95% change from the last price of €2.76.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","6":"€6","2.25":"€2.25","3.5":"€3.5","4.75":"€4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.95179255,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€2.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.95179255,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€2.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.95179255,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€2.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,2.774753273076923,2.789506546153846,2.804259819230769,2.819013092307692,2.8337663653846152,2.8485196384615383,2.8632729115384614,2.8780261846153845,2.8927794576923076,2.9075327307692307,2.922286003846154,2.937039276923077,{"y":2.95179255,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,2.774753273076923,2.789506546153846,2.804259819230769,2.819013092307692,2.8337663653846152,2.8485196384615383,2.8632729115384614,2.8780261846153845,2.8927794576923076,2.9075327307692307,2.922286003846154,2.937039276923077,{"y":2.95179255,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,2.774753273076923,2.789506546153846,2.804259819230769,2.819013092307692,2.8337663653846152,2.8485196384615383,2.8632729115384614,2.8780261846153845,2.8927794576923076,2.9075327307692307,2.922286003846154,2.937039276923077,{"y":2.95179255,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.601,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.183,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.42,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.94,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€2.95Average Price Target€2.95Lowest Price Target€2.95
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton
€7.13
Buy
158.15%
Upside
Reiterated
11/10/23
Bloom Burton Thinks HLS Therapeutics Inc's Stock is Going to Recover
Clarus
€9.68
Buy
250.61%
Upside
Reiterated
08/11/23
Clarus Sticks to Its Buy Rating for HLS Therapeutics Inc (HLS)
Raymond James
€6.11
Hold
121.27%
Upside
Reiterated
07/28/23
HLS Therapeutics Inc (HLS) Gets a Hold Rating from Raymond James
Canaccord Genuity Analyst forecast on DE:74D
Unknown Analyst
Not Ranked
Canaccord Genuity
€8.82
Buy
219.62%
Upside
Assigned
11/09/23
We estimate this equates to ~US$3.5M (+36% Y/Y), which missed our $3.8M forecast. Growth was negatively impacted by FX changes, but after a relatively quiet summer, growth in new prescriptions and ex-factory sales increased significantly in September. As a result, HLS reiterated its previous 2023 full-year revenue forecast of C$18.0-20.0M and still expects Vascepa to start making a positive contribution to adjusted EBITDA starting in H2/24.

Best Analysts Covering HLS Therapeutics Inc

Which Analyst Should I Follow If I Want to Buy DE:74D and Sell After:
1 Month
David Martin PhDBloom Burton
Success Rate
11/27 ratings generated profit
41%
Average Return
+12.80%
reiterated a buy rating 4 months ago
Copying David Martin PhD's trades and holding each position for 1 Month would result in 40.74% of your transactions generating a profit, with an average return of +12.80% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
David Martin PhDBloom Burton
Success Rate
12/27 ratings generated profit
44%
Average Return
+10.99%
reiterated a buy rating 4 months ago
Copying David Martin PhD's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +10.99% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
David Martin PhDBloom Burton
Success Rate
10/27 ratings generated profit
37%
Average Return
+9.56%
reiterated a buy rating 4 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 37.04% of your transactions generating a profit, with an average return of +9.56% per trade.
2 Years
David Martin PhDBloom Burton
Success Rate
6/27 ratings generated profit
22%
Average Return
-2.54%
reiterated a buy rating 4 months ago
Copying David Martin PhD's trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -2.54% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

74D Analyst Recommendation Trends

Rating
Oct 23
Nov 23
Dec 23
Jan 24
Feb 24
Strong Buy
6
4
3
2
0
Buy
0
0
0
0
0
Hold
0
1
2
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
5
5
5
3
In the current month, 74D has received 0 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 74D average Analyst price target in the past 3 months is €2.95.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

74D Financial Forecast

74D Earnings Forecast

Next quarter’s earnings estimate for 74D is -€0.09 with a range of -€0.12 to -€0.06. The previous quarter’s EPS was -€0.19. 74D beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.94% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.
Next quarter’s earnings estimate for 74D is -€0.09 with a range of -€0.12 to -€0.06. The previous quarter’s EPS was -€0.19. 74D beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.94% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.

74D Sales Forecast

Next quarter’s sales forecast for 74D is €14.77M with a range of €14.13M to €15.70M. The previous quarter’s sales results were €14.62M. 74D beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 63.08% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.
Next quarter’s sales forecast for 74D is €14.77M with a range of €14.13M to €15.70M. The previous quarter’s sales results were €14.62M. 74D beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 63.08% of the time in the same period. In the last calendar year 74D has Underperformed its overall industry.

74D Stock Forecast FAQ

What is DE:74D’s average 12-month price target, according to analysts?
Based on analyst ratings, HLS Therapeutics Inc’s 12-month average price target is €2.95.
    What is DE:74D’s upside potential, based on the analysts’ average price target?
    HLS Therapeutics Inc has 6.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HLS Therapeutics Inc a Buy, Sell or Hold?
          HLS Therapeutics Inc has a conensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
            What is HLS Therapeutics Inc’s share price target?
            The average share price target for HLS Therapeutics Inc is €2.95. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €2.95 ,and the lowest forecast is €2.95. The average share price target represents 6.95% Increase from the current price of €2.76.
              What do analysts say about HLS Therapeutics Inc?
              HLS Therapeutics Inc’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of HLS Therapeutics Inc?
                To buy shares of DE:74D, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis